Close Menu

orphan drug status

Experimental EGFR inhibitor fell short of desired objective response rate in patients with non-small cell lung cancer.

In a randomized trial, tucatinib with chemotherapy improved progression-free survival in patients with locally advanced or metastatic breast cancer.

Non-small cell lung cancer patients with EGFR mutations now have three treatment choices, and AstraZeneca is working on newer personalized treatment options.